Modified Benzofuran-carboxamide Compounds as Glucosylceramide Synthase Inhibitors for Treating Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 West Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2022 May 12;13(6):879-880. doi: 10.1021/acsmedchemlett.2c00182. eCollection 2022 Jun 9.
Abstract
摘要
相似文献
1
Modified Benzofuran-carboxamide Compounds as Glucosylceramide Synthase Inhibitors for Treating Diseases.作为用于治疗疾病的葡糖神经酰胺合酶抑制剂的修饰苯并呋喃 - 甲酰胺化合物
ACS Med Chem Lett. 2022 May 12;13(6):879-880. doi: 10.1021/acsmedchemlett.2c00182. eCollection 2022 Jun 9.
2
Can P-glycoprotein influence the bioavailability of iminosugar-based glucosylceramide synthase inhibitors?P-糖蛋白会影响基于亚氨基糖的葡萄糖神经酰胺合酶抑制剂的生物利用度吗？
Eur J Pharmacol. 2006 Jan 20;530(3):195-204. doi: 10.1016/j.ejphar.2005.11.038. Epub 2006 Jan 3.
3
Improved inhibitors of glucosylceramide synthase.改进的葡萄糖神经酰胺合酶抑制剂。
J Biol Chem. 1999 May 21;274(21):14662-9. doi: 10.1074/jbc.274.21.14662.
4
Fused Pyrazole Urea Analogs as Glucosylceramide Synthase Inhibitors for Treating Diseases.作为用于治疗疾病的葡糖神经酰胺合酶抑制剂的稠合吡唑脲类似物
ACS Med Chem Lett. 2023 Jul 6;14(8):1031-1032. doi: 10.1021/acsmedchemlett.3c00271. eCollection 2023 Aug 10.
5
Novel Fused Pyrazole Amide Analogs as Glucosylceramide Synthase Inhibitors for Treating Lysosomal Storage Diseases, Neurodegenerative Diseases, Cystic Diseases, and Cancer.新型稠合吡唑酰胺类似物作为葡糖神经酰胺合酶抑制剂用于治疗溶酶体贮积病、神经退行性疾病、囊性疾病和癌症。
ACS Med Chem Lett. 2023 Nov 8;14(12):1621-1622. doi: 10.1021/acsmedchemlett.3c00475. eCollection 2023 Dec 14.
6
Synthesis and cholinesterase inhibitory activity of new 2-benzofuran carboxamide-benzylpyridinum salts.新型 2-苯并呋喃甲酰胺-苄基吡啶翁盐的合成及胆碱酯酶抑制活性。
Bioorg Chem. 2018 Oct;80:180-188. doi: 10.1016/j.bioorg.2018.06.006. Epub 2018 Jun 6.
7
Inhibitors of Glucosylceramide Synthase.葡糖神经酰胺合酶抑制剂
Methods Mol Biol. 2023;2613:271-288. doi: 10.1007/978-1-0716-2910-9_20.
8
Synthesis and Evaluation of Hybrid Structures Composed of Two Glucosylceramide Synthase Inhibitors.由两种葡糖神经酰胺合酶抑制剂组成的杂化结构的合成与评价
ChemMedChem. 2015 Dec;10(12):2042-62. doi: 10.1002/cmdc.201500407. Epub 2015 Oct 23.
9
Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain.基于性质的葡萄糖神经酰胺合酶抑制剂设计，可降低大脑中的葡萄糖神经酰胺。
J Lipid Res. 2012 Feb;53(2):282-91. doi: 10.1194/jlr.M021261. Epub 2011 Nov 4.
本文引用的文献
1
Drugs repurposed: An advanced step towards the treatment of breast cancer and associated challenges.药物再利用：治疗乳腺癌及相关挑战的高级步骤。
Biomed Pharmacother. 2022 Jan;145:112375. doi: 10.1016/j.biopha.2021.112375. Epub 2021 Dec 1.
2
Role of hypothalamic de novo ceramides synthesis in obesity and associated metabolic disorders.下丘脑从头合成神经酰胺在肥胖及其相关代谢紊乱中的作用。
Mol Metab. 2021 Nov;53:101298. doi: 10.1016/j.molmet.2021.101298. Epub 2021 Jul 15.
3
Ceramide glycosylation and related enzymes in cancer signaling and therapy.神经酰胺糖基化及其相关酶在癌症信号转导和治疗中的作用。
Biomed Pharmacother. 2021 Jul;139:111565. doi: 10.1016/j.biopha.2021.111565. Epub 2021 Apr 20.
4
Sphingolipids in embryonic development, cell cycle regulation, and stemness - Implications for polyploidy in tumors.鞘脂在胚胎发育、细胞周期调控和干性中的作用——对肿瘤多倍体的影响。
Semin Cancer Biol. 2022 Jun;81:206-219. doi: 10.1016/j.semcancer.2020.12.027. Epub 2021 Jan 8.
5
Therapeutic advances in Fabry disease: The future awaits.法布瑞氏病的治疗进展：未来可期。
Biomed Pharmacother. 2020 Nov;131:110779. doi: 10.1016/j.biopha.2020.110779. Epub 2020 Sep 23.
6
Glycosphingolipid metabolism and polycystic kidney disease.糖脂代谢与多囊肾病。
Cell Signal. 2020 May;69:109526. doi: 10.1016/j.cellsig.2020.109526. Epub 2020 Jan 10.
Zotero 插件